September 13, 2004Journal of Clinical Oncology
Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
Why the study?
Does doxorubicin plus cyclophosphamide cause decreases in LVEF in women with HER2-positive breast cancer?
Population
1,458 women with human epidermal growth factor receptor 2-positive breast cancer enrolled in the North…
Design
Cohort, Patients were randomly assigned to subsequent treatments, but all…
Follow-up
3 weeks after completion of the fourth cycle
Authors
Discussion
Loading...
Member takes
Implication
Supports LVEF monitoring after AC in HER2-positive breast cancer; leaves open long-term clinical consequences.
Structured PICO
Does doxorubicin plus cyclophosphamide cause decreases in LVEF in women with HER2-positive breast cancer?
P
Population
1,458 women with human epidermal growth factor receptor 2-positive (node-positive or node-negative) breast cancer enrolled in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
I
Intervention
Standard doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) every 3 weeks for four cycles.
O
Outcome
Changes in left ventricular ejection fraction (LVEF) measured before and after four cycles of doxorubicin plus cyclophosphamide.safety
Standard doxorubicin plus cyclophosphamide chemotherapy is associated with frequent decreases in LVEF shortly after completion of four cycles in women with HER2-positive breast cancer.
Cite This Study
Perez et al. (2004) studied this question.